Overview

T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
We aim to translate these findings into patients with rheumatoid arthritis and other conditions treated with anti-TNF (anti-tumor necrosis factor) therapy, such as psoriatic arthritis and ankylosing spondylitis. Patients from rheumatology clinics within NHS (National Health Service) trusts will be recruited. We will correlate disease activity assessed by clinical parameters, ultrasonography, and questionnaires with biomarkers in the blood and target tissues, such as synovium and skin.
Details
Lead Sponsor:
Imperial College London
Treatments:
Adalimumab
Etanercept